|Mr. Gil Beyen BVBA||CEO & Director||536.31k||N/A||1962|
|Mr. Eric Soyer Ph.D.||Deputy GM, CFO & COO||365.41k||N/A||1966|
|Dr. Jérôme Bailly Pharm.D.||Deputy GM of Operations, Chief Quality Officer & Qualified Person||224.92k||N/A||1979|
|Naomi Eichenbaum||Director Investor Relations||N/A||N/A||N/A|
|Mr. Brian Schwab||Chief Legal Officer & Gen. Counsel||N/A||N/A||1965|
|Ms. Anne-Cécile Fumey||HR Director||N/A||N/A||1975|
|Dr. Iman El-Hariry M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1960|
|Dr. Philip L. Lorenzi||Consultant & Member of Scientific Board||N/A||N/A||N/A|
|Prof. Eric Raymond M.D., Ph.D.||Consultant & Member of Scientific Board||N/A||N/A||N/A|
|Dr. Bridget Bax||Consultant & Member of Scientific Board||N/A||N/A||N/A|
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
ERYTECH Pharma S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.